Drug Search Results
More Filters [+]

Zanamivir

Alternative Names: zanamivir, relenza
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NEU Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zanamivir

Countries in Clinic: Colombia, Netherlands, Poland, Spain, United Kingdom

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Arthralgia|Influenza, Human

Phase 1: Dengue

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT04494412

P2

Recruiting

Influenza, Human|Arthralgia

2026-12-09

25%

200925

P2

Recruiting

Influenza, Human

2026-12-09

ZAP-DENGUE

P1

Recruiting

Dengue

2025-09-30

Zanamivir, Ph 2a, Infant/Neonate complicated Influenza Patients,5-10 Day IV RD, PK/Safety Study

P2

Active, not recruiting

Influenza, Human

2023-11-29

Recent News Events